VolitionRx’s Nu.Q cancer test shows efficacy in lung cancer detection

VolitionRx (VNRX) announced the results of a large-scale study which shows that its Nu.Q Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT or LDCT scan, in patients suspected of lung cancer. Findings published in a paper that is currently undergoing peer review and accessible on MedRXIV, conclude that a panel of two Nu.Q nucleosome quantification assays showed a diagnostic sensitivity of 92% and a Positive Predictive Value of 89% in identifying cancerous nodules when used in combination with LDCT screening. The validation study is set to begin this year and due for completion in 2025, potentially leading to the inclusion of the Nu.Q Cancer test in Taiwan’s National Lung Cancer Screening Program.